Dictionary

The Dictionary provides concise definitions of health economics terms, arranged alphabetically for quick reference. Use it to understand unfamiliar terminology or confirm the meaning of a specific term.

101150 of 249 terms matching Risk

C

Cardiac Rehabilitation
A structured, supervised programme of exercise, education, and lifestyle counselling for patients recovering from a cardiac event, reducing future risk.
Cardiovascular Epidemiology
A branch of epidemiology studying the distribution and determinants of cardiovascular disease, including major modifiable and non-modifiable risk factors.
Cardiovascular Prevention
Interventions reducing cardiovascular disease incidence by modifying risk factors, such as blood pressure, cholesterol, and smoking, spanning public health and clinical measures.
Cause-Specific Survival
The probability of surviving without dying from a specific cause of interest, treating deaths from other causes as censoring rather than a competing risk.
Chronic Disease Epidemiology
A branch of epidemiology studying the distribution, risk factors, and natural history of long-lasting, non-communicable conditions such as diabetes and heart disease.
Classification Methods
Statistical and machine learning techniques assigning individuals or observations into predefined categories based on their characteristics, such as risk level.
Community Rating
A method setting premiums that charges all enrollees within a community the same rate, or within narrow limits, regardless of individual risk.
Confounding by Indication
Confounding in pharmacoepidemiology arising when the reason for prescribing a treatment is itself linked to a patient's underlying risk of the outcome studied.
Consolidation Therapy
A treatment given after successful induction therapy has reduced disease burden, intended to eliminate remaining disease and reduce relapse risk.
Constant Hazard
A survival pattern where the instantaneous risk of an event stays the same at every point in time, matching an exponential distribution.
Cost-of-Illness StudyCOI Study
A cost-of-illness study is a descriptive economic analysis that identifies, measures and values the healthcare resource use, patient and caregiver costs, productivity losses and other economic consequences attributable to a disease, injury or risk factor in a defined population and period.
Cream Skimming
A practice where an insurer or provider selectively attracts healthier, lower-cost enrollees while avoiding sicker ones, undermining risk pooling.
Cumulative Hazard
The total accumulated risk of an event by a given point in time, found by integrating the instantaneous hazard rate up to that point.
Cumulative Incidence
The proportion of an initially disease-free population that develops a specific outcome over a defined follow-up period, a measure of average risk.
Cure Fraction
The proportion of a population modelled as having no residual risk of the disease-specific event after successful treatment, effectively behaving as cured.
Cure Fraction Model
A survival model separating a population into a cured subgroup facing only background mortality and an uncured subgroup remaining at risk of the disease event.
Cure Model
A survival model assuming a defined proportion of a population will never experience the event of interest, distinguishing this cured group from those still at risk.

D

Deep Vein Thrombosis
A condition in which a blood clot forms within a deep vein, usually the leg, risking travel to the lungs as a pulmonary embolism.
Delayed Care
A coping strategy in which a household postpones seeking needed healthcare due to cost concerns, risking a worsening condition.
Demographic Adjustment
A risk adjustment method predicting expected costs based on basic characteristics, such as age and sex, without detailed clinical diagnosis information.
Dependent Censoring
A survival analysis situation in which the reason for censoring is related to a participant's underlying risk of the event, violating standard assumptions.
Deprescribing
The planned, supervised process of reducing or stopping a medication no longer beneficial or causing harm, managing polypharmacy and related risk.
Diabetes Screening
Testing conducted to identify people with undiagnosed diabetes or at high risk, typically targeting populations with known risk factors.
Diabetic Neuropathy
A diabetes complication involving nerve damage, most commonly in the feet and legs, risking pain, numbness, and foot ulcers.
Diagnostic Analytics
The application of data analysis techniques to support diagnostic decision-making, from statistical risk prediction models to machine learning algorithms trained on clinical data.
Digital Evidence Framework
A structured methodology determining the type and quality of evidence required to evaluate a digital health technology, calibrated to its risk and complexity.
Do Not Do
A formal recommendation identifying a practice or treatment that should no longer be used, evidence indicating insufficient benefit relative to cost or risk.
Drug-Drug Interaction
An alteration in a drug's effect caused by another medication present at the same time, increasing or decreasing effect or adverse risk.
Dynamic Transmission Model
An epidemiological model representing how infection risk for a susceptible individual depends on current population prevalence, capturing feedback such as herd immunity.

E

Economic Burden
The total cost imposed on a health system, individuals, or society by a specific disease, injury, or risk factor.
Effect Measure Modification
A situation where an exposure-outcome association's magnitude differs by which effect measure is used, such as relative risk versus risk difference.
Environmental Health Policy
Government policy addressing health risks from environmental exposures, such as air pollution or contaminated water, covering regulatory standards and remediation.
Ethics Committee
A body responsible for reviewing the ethical acceptability of proposed research or clinical practices, evaluating risk, merit, and adherence to principles.
Excess Hazard
The additional death risk attributable specifically to the disease studied, the difference between total observed hazard and the background hazard in a comparable population.
Excess Mortality
The additional death risk attributable to a specific condition, the difference between an affected population's observed mortality and that of a comparable unaffected group.
Exponential Distribution
A probability distribution characterised by a constant hazard rate over time, used to model event timing when risk is assumed not to change.
Extended Cost-EffectivenessECEA
A form of economic evaluation that extends standard cost-effectiveness analysis by incorporating financial risk protection and the distribution of costs and benefits by income.

F

Frailty Model
A survival model incorporating an unobserved random effect, called frailty, to represent risk heterogeneity not captured by observed covariates.
Free Rider Problem in Insurance
The tendency for healthy individuals to skip buying insurance while relying on emergency care or others' willingness to fund risk pools.
Full Capitation
A capitation arrangement in which a provider assumes complete financial risk for essentially all a patient's healthcare costs, unlike partial capitation.
Fully Insured Plan
An arrangement where an employer purchases coverage from an insurer that assumes the financial risk for claims, unlike a self-insured plan.

G

Genetic Screening
The systematic testing of individuals or populations for genetic variants associated with disease risk, to identify who may benefit from targeted prevention or treatment.
Genetic Testing
Laboratory analysis of an individual's DNA to identify genetic variants associated with disease risk, diagnosis, or treatment response.
Genomic Analytics
The application of data analysis to genomic and genetic data, identifying disease risk factors and guiding treatment selection.
Genomic Data
Information derived from an individual's genetic material, such as gene sequences or variants, used to study disease risk or treatment response.
Genomic Medicine
An approach to healthcare incorporating an individual's genomic information into clinical decision-making, spanning diagnosis, risk assessment, and treatment selection.
Global Burden of DiseaseGBD
A research programme systematically quantifying the health loss caused by diseases, injuries, and risk factors across countries and time, using disability-adjusted life years.
Global Payment
A comprehensive payment covering all or nearly all of a patient's healthcare needs over a defined period, placing substantial financial risk on the provider.

H

Hazard Function
A function describing the instantaneous risk of an event at a given point in time, conditional on having survived to that point.
Hazard RatioHR
A measure comparing the instantaneous risk of an event in one group relative to another, commonly estimated using a Cox model.